We found an overrepresentation of HER2-positive, HR-negative and triple-negative tumours among MBC patients diagnosed with CNS metastases, suggesting that tumour biology impacts the risk of CNS involvement in breast cancer. This evidence concerns the gene ERBB2 and neoplasm.